Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of trastuzumab emtansine in HER2-overexpressing solid tumors
2015-001377-40Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab emtansine in bladder cancer, pancreatic cancer (PC) and cholangiocarcinoma (CCA) (2 cohorts), sponsored by Roche. Primary endpoint: Best overall response rate. Started Aug 2016; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
bladder cancerpancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2015-001377-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001377-40.